Urothelial Carcinoma Diagnostics
Advertisement
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Liquid biopsy can benefit patients with UTUC by detecting rare events at higher incidences compared to tissue-based samples.
Researchers investigated the ability of variant histology to predict oncological outcomes.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Dr. Li details what his study results suggested about ctDNA’s prognostic implications for survival in patients with UTUC.
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
Researchers used whole-genome sequencing and a 152-gene panel to study the DNA of patients with high-risk UTUC.
Investigators performed IHC of 4 DNA mismatch repair gene-related proteins (MMRPs) on all UTUC specimens.
PET patients were more likely to have a change in treatment compared with receiving CT alone.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
Drs. Koshkin and Basu discuss how ctDNA are being evaluated for disease recurrence, response monitoring in advanced UC.
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.